Equities

QuiaPEG Pharmaceuticals Holding AB

QuiaPEG Pharmaceuticals Holding AB

Actions
  • Price (SEK)0.0729
  • Today's Change-0.001 / -1.22%
  • Shares traded1.70m
  • 1 Year change-95.01%
  • Beta1.2462
Data delayed at least 15 minutes, as of Apr 26 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-16.52m
  • Incorporated2004
  • Employees8.00
  • Location
    QuiaPEG Pharmaceuticals Holding ABUppsala Business ParkVirdings Alle 32 BUPPSALA 754 50SwedenSWE
  • Phone+46 87780006
  • Fax+46 87780005
  • Websitehttps://www.quiapeg.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
XP Chemistries AB663.69k-8.04m3.55m2.00--0.1382--5.35-0.2846-0.28460.02130.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79--0.00---37.14---1.55------
QuiaPEG Pharmaceuticals Holding AB0.00-16.52m5.43m8.00--0.3561-----3.51-3.510.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
European Institute of Science AB600.00k-2.72m6.02m0.00--1.49--10.03-4.25-4.250.93972.980.17280.84798.63---78.21-93.04-82.77-103.1462.3367.01-452.67-518.8210.54------13.698.540.4062------
Bio Vitos Pharma AB2.98m-12.87m6.36m1.00--1.6512.382.13-0.2547-0.25470.05330.11190.09890.005.382,983,990.00-42.63-31.11-44.50-32.92100.00---431.21-1,026.764.27--0.00--126.97--13.64------
Lipidor AB77.00k-11.49m6.81m--------88.44-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
Stayble Therapeutics AB0.00-23.74m7.41m3.00--0.4487-----0.9492-0.94920.000.52040.00----0.00-116.21-78.64-141.76-95.58------------0.049------3.22------
2cureX AB155.00k-30.82m7.85m----0.5735--50.65-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Amniotics AB (publ)0.00-30.87m10.39m6.00--0.6629-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Eurocine Vaccines AB5.00k-15.06m10.55m3.00------2,111.00-0.1472-0.14720.00005-0.00180.0007--0.002---199.76-83.17-323.19-97.89-199,780.00---301,180.00--------------8.95------
Lidds AB0.00-40.21m10.88m2.00--0.783-----0.7253-0.72530.000.20370.00----0.00-184.53-46.33-274.92-51.61-------3,076.68---------100.00---9.08------
Aptahem AB32.00k-11.11m13.36m----0.1306--417.60-0.0497-0.04970.00010.22660.0005--0.0738---16.76-39.26-19.47-44.194,623.59---34,727.72-----10.170.0847-------25.36------
Data as of Apr 26 2024. Currency figures normalised to QuiaPEG Pharmaceuticals Holding AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.